Showing results (141-150 of 792) with videos related to
Sort By:
Pageof 80
Blood Cancer Journal|April 12, 2022
Cutaneous manifestations of monoclonal gammopathyJean-Sebastien Claveau, David A Wetter, Shaji KumarJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Thalidomid: current role in the treatment of non-plasma cell malignanciesShaji Kumar, Thomas E Witzig, S Vincent RajkumarExpert Review of Hematology|January 8, 2014
Initial treatment of transplant-eligible patients in multiple myelomaLaura Rosiñol, Shaji Kumar, Phillipe Moreau, et al.Blood Cancer Journal|May 29, 2026
Monoclonal gammopathy of clinical significance: a multisystem reviewManraj Singh Sra, S Vincent Rajkumar, Shaji KumarBritish Journal of Haematology|May 19, 2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trialPaul G Richardson, Robert L Schlossman, Anuja N Roy, et al.Oncotarget|August 4, 2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylationShardule P Shah, Ajay K Nooka, David L Jaye, et al.Journal of Oncology Practice|July 12, 2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and ElotuzumabAjay K Nooka, Charise Gleason, Marva Ollivierre Sargeant, et al.Expert Review of Clinical Pharmacology|October 28, 2015
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomesPaul G Richardson, R Donald Harvey, Jacob P Laubach, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2019
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaSagar Lonial, Susanna Jacobus, Rafael Fonseca, et al.British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.Pageof 80